(Q37205563)

English

Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry

scientific article published on 19 February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

inflammatory breast cancer

1 reference

based on heuristic

inferred from title

Hoda Anton-Culver

5

object named as

Hoda Anton-Culver

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Jason A Zell

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Walter Y Tsang

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Thomas H Taylor

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Rita S Mehta

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

publication date

19 February 2009

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Breast Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

R9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Prognostic significance of HER-2 status in women with inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Inflammatory breast cancers in Tunisia and France show similar immunophenotypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Clinical aspects of inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Short- and long-term cause-specific survival of patients with inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

6 September 2017

Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988-2000.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

14 September 2017

WISP3 is a novel tumor suppressor gene of inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

28 September 2017

Trastuzumab in inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

26 June 2018

The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

26 June 2018

Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

High incidence of HER-2 positivity in inflammatory breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Socioeconomic status and breast cancer incidence in California for different race/ethnic groups

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Breast cancer in Tunisia: clinical and epidemiological study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687713

3 September 2018

Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1186%2FBCR2225

21 January 2018

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trends for Inflammatory Breast Cancer: Is Survival Improving?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19228416

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/BCR2225

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37205563&oldid=2200023545"